T Cell Equipment
-
Manufactured by Trailhead Biosystems Inc.based in USA
We are developing cell culture media for T-cell subtype control to improve clinical potency in the individual patient and reduction of variability in outcomes between patients. CAR T-cell therapy involves the treatment of cancer by modifying a patient’s T-cells in the lab ...
-
based in USA
We are exploiting the unique immunology of human cytomegalovirus, or HCMV, a commonly occurring virus in humans, as a delivery vehicle – or vector – for vaccines to potentially treat and prevent infection by pathogens that are refractory to current vaccine technologies. HCMV is the most potent known inducer of T cell responses of ...
-
Manufactured by Cartherics Pty ltdbased in AUSTRALIA
This technology arms the patient’s own T cells with CARs, which enable them to “seek and destroy” cancer ...
-
Manufactured by Oxford Vacmedix UK Limitedbased in UNITED KINGDOM
In the image below the Recombinant Overlapping Peptide is the “Antigen” being presented to the T Cell Receptor (TCR). This then triggers the growth of T Cells that will recognise the same marker on cancer cells leading to their destruction. ...
-
based in FRANCE
Regulatory T cells (Tregcells) represents a cell population with strong immunosuppressive activities. In cancer patients, Treg cells can dampen protective immune responses against tumor antigens. Moreover, high infiltration by Treg cells has been associated with poor survival invarious types of cancer. ...
-
Manufactured by Sana Biotechnologybased in USA
Oncology: Multiple ...
-
Manufactured by Sana Biotechnologybased in USA
Oncology: Multiple ...
-
Manufactured by Adaptimmune LLCbased in USA
Our ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types. The MAGE- A4 antigen is among the most commonly expressed cancer-testis antigens. We are conducting various trials with the ADP-A2M4 SPEAR T-cell in ...
-
Manufactured by Adaptimmune LLCbased in USA
Our ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a member of the MAGE family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher grade tumors. Please note that the two trials with ADP-A2M10 are now closed for ...
-
Manufactured by Adaptimmune LLCbased in USA
Our ADP-A2M4CD8 SPEAR T-cell therapy is our first "next-generation" therapy and is directed to MAGE-A4, a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. What differentiates this therapy from our ADP-A2M4 SPEAR T-cells is that these cells also express the CD8α ...
-
Manufactured by IN8Bio Inc.based in USA
INB-300, our DeltEx DRI CAR-T, is a preclinical product candidate combining our expertise in gamma-delta T cells, our DRI technology and a novel CAR-directed against the Cholotoxin peptide. Chlorotoxin binds to GBM tumor cells and has been previously utilized as a tumor paint in this setting. Chlorotoxin can also bind to other ...
-
Manufactured by TC BioPharmbased in UNITED KINGDOM
Our therapies are focused on leveraging the inherent biological capabilities of gamma delta T cells (GDT cells) together with an integrated cell engineering approach. GDT cells are a component of the lymphocytes (white blood cells) present within all humans, representing approximately 1-5% of the ...
-
Manufactured by Adicet Biobased in USA
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet to be proven. The cell platform and novel ...
-
Manufactured by Sana Biotechnologybased in USA
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
-
Manufactured by T-Cure BioScience, Inc.based in USA
T cell engineering with TCRs is a growing area of immuno-oncology with recent breakthroughs in clinical settings. The T-Cure approach involves identifying and isolating a high avidity TCR which specifically recognizes an intracellular or cell-surface target in solid tumors. This TCR is then typically introduced into a viral ...
-
Manufactured by Adaptimmune LLCbased in USA
Our ADP-A2AFP SPEAR T-cell product targets alpha-fetoprotein (AFP) is being investigated in an ongoing Phase 1 clinical trial for the treatment of patients with hepatocellular carcinoma (liver ...
-
Manufactured by LAVA Therapeutics N.V.based in NETHERLANDS
Vγ9Vδ2 T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the ...
-
Manufactured by Takeda Pharmaceutical Company Limitedbased in JAPAN
Adaptate Biotherapeutics is focussed on therapeutic antibodies which harness the potential of patients’ own gamma delta T cells in situ. Gamma delta T cells play a critical role in immune surveillance, recognising malignant/transformed cells through a pattern of stress markers and exerting potent ...
-
Manufactured by IN8Bio Inc.based in USA
Our DeltEx platform has enabled a deep pipeline of preclinical and clinical product candidates, which are designed to effectively target and potentially eradicate disease, to improve patient ...
-
Manufactured by Adaptimmune LLCbased in USA
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune therapies and cancer therapies. The video below ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you